

Pharmacy Program Updates: Prior Authorization Changes Effective June 15, 2024

April 10, 2024

The Blue Cross and Blue Shield of Illinois prior authorization program encourages safe, cost-effective medication use by allowing coverage when certain conditions are met. A clinical team of physicians and pharmacists develops and approves the clinical programs and criteria for medications that are appropriate for PA by reviewing U.S. Food and Drug Administration approved labeling, scientific literature, and nationally recognized guidelines.

Please see the table below for the upcoming changes to the standard PA programs. These changes impact BCBSIL members who have prescription drug benefits administered by Prime Therapeutics.

Effective Date	PA Program	Description of	Drug Lists	PA or
June 15, 2024	Agamree Emflaza	Change New criteria	Basic, Basic	Specialty PA Specialty PA
Julie 15, 2024	PAQL	requirement and new	Annual,	Specially FA
	TAQL	program target	Enhanced,	
		program target	Enhanced	
			Annual, 2023	
			Health Insurance	
			Marketplace,	
			2024 HIM,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	
			Performance	
			Select	
June 15, 2024	Empaveli PAQL	New criteria	Basic, Basic	Specialty PA
Julio 10, 2024	Linpaveti i AQL	requirement	Annual,	opecially 171
		requirement	Enhanced,	
			Enhanced	
			Annual, 2023	
			HIM, 2024 HIM,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	
			Performance	
			Select	
June 15, 2024	Galafold PAQL	New criteria	Basic, Basic	Specialty PA
, , , , , , , , , , , , , , , , , , , ,		requirements	Annual,	
		i squii siii siii s	Enhanced,	
			Enhanced	
			Annual, 2023	
			HIM, 2024 HIM,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	

			Performance	
			Select	
June 15, 2024	Self-Administered Oncology Agents PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced,	Specialty PA
			Performance, Performance Annual and Performance Select	
June 15, 2024	Tarpeyo PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	PA
July 1, 2024	Biologic Immunomodulators PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	Specialty PA
July 1, 2024	Erythropoietins PA	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	Specialty PA
July 1, 2024	Fabhalta PAQL	New program	Basic Basic Annual, Enhanced, and Enhanced Annual	Specialty PA

July 1, 2024	Fintepla PAQL	New criteria	Basic, Basic	PA
July 1, 2024	Тіпієріа РАС	requirements	Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced,	FA
			Performance, Performance Annual and	
			Performance Select	
July 1, 2024	GLP-1 Agonists PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual,* 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	PA
July 1, 2024	HCPA Biologic Immunomodulators PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, and Enhanced Annual	Specialty PA
July 1, 2024	Homozygous Familial Hypercholesterolemia (HoFH) Agents PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	Specialty PA
July 1, 2024	PCSK-9 Inhibitors PAQL	New criteria requirements	Basic, Basic Annual, Enhanced, Enhanced Annual, 2023 HIM, 2024 HIM, Balanced, Performance, Performance Annual and Performance Select	PA
July 1, 2024	Therapeutic Alternatives PAQL	New program targets	Basic, Basic Annual,	PA

	_	1		
			Enhanced,	
			Enhanced	
			Annual, 2023	
			HIM, 2024 HIM,	
			Balanced,	
			Performance,	
			· ·	
			Performance	
			Annual and	
			Performance	
			Select	
July 1, 2024	Xolair PA	New criteria	Basic, Basic	Specialty PA
		requirements	Annual,	
			Enhanced,	
			Enhanced	
			Annual, 2023	
			HIM, 2024 HIM,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	
			Performance	
			Select	
July 1, 2024	Xphozah PAQL	New program	Basic, Basic	PA
			Annual,	
			Enhanced, and	
			Enhanced Annual	
July 1, 2024	Zoryve PA	New criteria	Basic, Basic	PA
July 1, 2024	Zoryver A	requirements		17
		requirements	Annual,	
			Enhanced,	
			Enhanced	
			Annual, 2023	
			HIM, 2024 HIM,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	
			Performance	
			Select	
July 15, 2024	Weight Loss Agents	New criteria	Basic, Basic	PA
July 15, 2024				ГA
	PAQL	requirements	Annual,	
			Enhanced,	
			Enhanced	
			Annual,	
			Balanced,	
			Performance,	
			Performance	
			Annual and	
			Performance	
			Select	
			361601	

Please visit the <u>Prior Authorization and Step Therapy Programs</u> section for a list of programs and target drugs, as well as the PA request form and more information.

As a reminder, treatment decisions are always between you and your patients. Coverage is subject to the terms and limits of your patients' benefit plans. Please advise them to review their benefit materials for details.

If your patients have any questions about their pharmacy benefits, please advise them to contact the number on their BCBSIL member ID card. Members may also visit <u>our member site</u> and log in to Blue Access for MembersSM or <u>MyPrime.com</u> for a variety of online resources.

Prime Therapeutics LLC is a pharmacy benefit management company. BCBSIL contracts with Prime to provide pharmacy benefit management and related other services. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime. MyPrime.com is an online resource offered by Prime Therapeutics.

The information mentioned here is for informational purposes only and is not a substitute for the independent medical judgment of a physician. Physicians are to exercise their own medical judgment. Pharmacy benefits and limits are subject to the terms set forth in the member's certificate of coverage which may vary from the limits set forth above. The listing of any particular drug or classification of drugs is not a guarantee of benefits. Members should refer to their certificate of coverage for more details, including benefits, limitations and exclusions. Regardless of benefits, the final decision about any medication is between the member and their health care provider.

Checking eligibility and benefits and/or obtaining prior authorization is not a guarantee of payment of benefits. Payment of benefits is subject to several factors, including, but not limited to, eligibility at the time of service, payment of premiums/contributions, amounts allowable for services, supporting medical documentation, and other terms, conditions, limitations, and exclusions set forth in the member's policy certificate and/or benefits booklet and or summary plan description. Regardless of any prior authorization or benefit determination, the final decision regarding any treatment or service is between the patient and the health care provider. If you have any questions, call the number on the member's BCBSIL ID card.